Increase in incidence of cancer, rise in the global geriatric population, and surge in government expenditure on healthcare have boosted the global oncology/cancer drugs market. However, adverse effect associated with use of cancer drugs hinders the market growth. On the contrary, rise in number of pipeline drugs and high growth potential in untapped emerging economies …
Continue reading “In the Crowded Oncology/Cancer Drugs Market, There’s Room for Revenue Growth”